Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors

Group 1 - Nuvation Bio Inc. (NYSE:NUVB) is recognized as a high short interest stock with significant upside potential, particularly due to the performance of its Ibtrozi franchise [1] - Truist raised its price target for Nuvation Bio to $13 from $11, maintaining a Buy rating, citing strong market uptake for Ibtrozi as a preferred ROS1 agent [1] - RBC Capital analyst increased the price target for Nuvation Bio to $12 from $9 with an Outperform rating after discussions with management, leading to updates in financial models for the biotech sector [2] Group 2 - H.C. Wainwright adjusted its price target for Nuvation Bio to $17 from $18 while keeping a Buy rating, noting that preliminary Q4 Ibtrozi net product revenue was approximately $15.7 million, aligning with expectations [3]